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Abstract 30 
Objective: The main objective of this systematic review of the literature was to determine the 31 
accuracy of on-site tests that require fewer resources to detect asymptomatic bacteriuria among 32 
pregnant women. 33 
Data source: We searched the main electronic bibliographic databases from inception until 34 
June 2015 without language restrictions.  35 
Methods of Study Selection: Two independent reviewers selected studies that recruited 36 
asymptomatic pregnant women to evaluate the accuracy of on-site tests in detecting the 37 
presence of bacteria in the urine using urine culture as a reference standard. 38 
Tabulation, Integration, and Results: Data on women’s characteristics, study design, sample 39 
collection, and handling were extracted along with to 2 x 2 tables, and synthesized, where 40 
possible, using a bivariate, hierarchical random effects model. Of 1,360 screened references, 27 41 
papers (13,641 women) with test accuracy data on nine tests met the inclusion criteria. The 42 
most commonly evaluated test was urine dipstick. The pooled sensitivity and specificity of the 43 
dipstick to detect nitrites were 0.55 (95% CI 0.42 to 0.67) and 0.99 (95% CI 0.98 to 0.99), 44 
respectively. Griess test to detect nitrites had a sensitivity of 0.65 (95% CI 0.50 to 0.78) and 45 
specificity of 0.99 (95% CI 0.98 to 1·00). Dipslide with gram staining had a pooled sensitivity 46 
of 0.86 (95% CI 0.80 to 0.91) and specificity of 0.97 (95% CI 0.93 to 0.99). 47 
Conclusions: The sensitivity of evaluated on-site tests to exclude bacterial urinary infection 48 
varies, however, their specificity to rule in disease is high. 49 
Registration number: PROSPERO No. CRD42015027905  50 
Keywords: test accuracy, asymptomatic bacteriuria, pregnancy, on-site test 51 
  52 
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Introduction  53 
Asymptomatic bacteriuria, a common urinary tract infection, varies in prevalence by factors such 54 
as age, gender, level of sexual activity, etc. The prevalence of the infection in pregnancy ranges 55 
from 2–15% of whom 20–40% progress to symptomatic urinary infections (UTI).1 Pregnant 56 
women with undetected asymptomatic bacteriuria are more likely to deliver prematurely2 or low-57 
birth-weight infants, and have a 20- 30-fold increased risk of developing pyelonephritis compared 58 
with those without the infection.3 59 
 60 
Although some bodies recommend a routine urine culture screening in early pregnancy4, 5, it is 61 
an expensive, cumbersome, and time-consuming test (taking 24 to 48 hours to obtain results) that 62 
requires access to laboratory facilities. There is a wide range of tests requiring fewer resources 63 
and minimal training,6 of which the most commonly used to detect the presence of bacteria 64 
instantly in the urine is a dipstick. Available evidence synthesis on their accuracy in pregnancy 65 
is limited in range of evaluated test7, and methodological strength.6, 8 66 
 67 
We bridge the above gap through a systematic and comprehensive evaluation of a wide range of 68 
on-site tests used to detect bacteriuria compared against urine culture as a reference standard in 69 
asymptomatic pregnant women taking into account potential sources of heterogeneity. 70 
 71 
Methods 72 
The review was conducted prospectively guided by a pre-defined protocol (PROSPERO No. 73 
CRD42015027905). We followed current standards of evidence synthesis for test accuracy9-11 74 
and reported findings in compliance with guidelines.12 75 
 76 
Sources 77 
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We searched major databases such as Medline, Embase, Web of Science, Scopus, and a 78 
specialized database of Latin-American literature (LILACS) for studies published from 79 
database inception to August 2014, with no language restrictions. The search was updated to 80 
June 2015. The search strategy combined terms such as: ‘Pregnancy’, ‘Antenatal’, ‘Gestation’, 81 
’asymptomatic bacteriuria’ and ‘Urinary Tract Infections’ and applied a filter for test accuracy 82 
studies (for details see Appendix 1).13 83 
 84 
Study selection 85 
Two independent reviewers (ER and SF) screened references and full-text of previously 86 
selected articles. The consensus on the eligibility of evaluated publications was reached through 87 
discussion, or consultation with a third reviewer (KSK). We looked for studies reporting the 88 
accuracy of any on-site tests to detect asymptomatic bacteriuria among pregnant women 89 
without symptoms of urinary tract infections or not on antibiotic treatment. The reference 90 
standard had to be a urine culture, and asymptomatic bacteriuria had to be defined as equal, or 91 
more than 105 Colony Forming Units of a single organism per mL of urine.8 Test accuracy had 92 
to be reported in a way allowing construction of 2 x 2 tables. We excluded studies with a case-93 
control design and were reference standard was not reported or used a different definition of 94 
bacteriuria than specified above as this design and variation in reference standard were 95 
associated with bias.14 96 
 97 
Data were extracted independently by ER and SF on to a piloted sheet. We collected authors’ 98 
details, year of publication, country, women’s characteristics, gestational age at testing; urine 99 
collection method, storage, and handling. The data were tabulated, crossed checked and in the 100 
case of discrepancies discussed between the reviewers. The studies were grouped according to 101 
country income (low-, low-middle, upper-middle) using the World Bank classification.15 The 102 
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risk of bias and applicability of included studies were assessed by two independent reviewers 103 
(ER and SF) using the QUADAS-2 tool10 tailored for this review. Study quality was assessed 104 
for selection of participants, implementation of the index test and the reference standard, and 105 
patient flow. Studies with low risk of bias used a suitable spectrum of participants, recruited in 106 
consecutive or random manner; all participants were tested using the same reference standard, 107 
and the majority of the study population was included in analyses. Any disagreements over 108 
quality assessment were resolved by a third reviewer (KSK). We did not assess publication bias 109 
due to limitations of available methods.16, 17 110 
 111 
We calculated test accuracy estimates (sensitivity, specificity, and likelihood ratios for positive 112 
and negative test result) with 95% confidence intervals (CIs). Heterogeneity was investigated 113 
visually on forest plots with sensitivity and specificity estimates (with 95% confidence 114 
intervals) for individual studies. The impact of quality of study design, the reliability of 115 
population description, and sample collection and storage was explored through sensitivity 116 
analyses. All analyses were conducted using STATA version 12.1.18 If less than required 117 
number of data points was available, we pooled accuracy of sensitivity and specificity, and 118 
likelihood ratios using univariate model using metaprop and metan commands, respectively. 119 
Where a higher number of studies was available, we pooled the accuracy parameters using 120 
bivariate, random effects model as implemented in metandi19 and midas20 commands . Posttest 121 
probabilities were calculated using following formula: O= p1/(1 - p1 ), p2 = O * L, p = p2 /(1 + 122 
p2), where p1 pretest probability, O pretest odds, p2 posttest odds, L likelihood ratio, p posttest 123 
probability.21  124 
 125 
 126 
Results 127 
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Out of the 1,360 references, 39 examining 27 types of index tests appeared initially to meet the 128 
inclusion criteria (Figure 1). After exclusion of tests not suitable for use in the asymptomatic 129 
population, we were left with 27 studies with nine index tests. List of all identified tests and 130 
reasons for study exclusion can be found in Appendix 2. Selected tests were: dipstick with only 131 
nitrites marker as positive, dipstick with nitrites or leucocytes as positive, urine analysis with 132 
bacteria count, dipslide with gram stain, Uricult (Orion Diagnostica, Espoo, Finland), 133 
Microstix-3 (Bayer Schering Pharma, Berlin, Germany), Griess test to detect nitrites, 134 
chlorhexidine reaction, and uriscreen catalase test. Reference of the included studies can be 135 
accessed in Appendix 3. 136 
 137 
The majority of identified studies were conducted in low-middle (11 studies) or upper-middle 138 
(five studies) income countries; ten in high-income countries and only one in a low-income 139 
country. The studies were published between 1981 and 2015; ten studies were published before 140 
the year 2000, nine between 2000 and 2010 and remaining eight in the last five years. The 141 
majority (19/27) of included studies contributed to evidence synthesis accuracy data of only 142 
one test (Table 1) with urine dipstick as the most commonly reported test. Urine was mostly 143 
collected through clean catch midstream technique and as a random voided or first-morning 144 
sample in 56% of studies (15/27). Use of sterile containers was mentioned in ten out of 27 145 
studies. More details on urine sample collection, handling and storage, and the details of urine 146 
culture incubation can be found in Appendix 4. 147 
 148 
The overall quality of included studies was moderate (Figure 2). Twelve out of 27 studies gave 149 
a proper description of patients’ selection with the remaining not giving enough details to 150 
assess this methodological aspect of the study. There was no concern for risk of bias due to 151 
index test implementation in over 80% of the studies (22/27). Similarly, for the reference 152 
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standard except two studies, the performance of the urine culture was classified as high risk of 153 
bias. Flow and timing were described with sufficient details in one-third of studies (9/27). The 154 
high concern over the applicability of findings was due to the type of the reference standard in 155 
five studies and the index test in one case. The main concern in the case of the reference 156 
standard was the use of a double urine culture to confirm the diagnosis of bacterial infection. 157 
 158 
Twenty-one studies (9,491 women) reported accuracy data for the detection of nitrites using 159 
urine dipstick and eight for the combination of positive nitrites or leukocytes (5,940 women). 160 
The average prevalence of asymptomatic bacteriuria in these studies were 0.08 (95% CI 0.06 to 161 
0.10). The pooled sensitivity of urine dipstick for positive nitrites in detecting infection was 162 
0.55 (95% CI 0.42 to 0.67) with specificity 0.99 (95% CI 0.98 to 0.99). The pooled sensitivity 163 
of positive nitrites or leukocytes was 0.73 (95% CI 0.59 to 0.83) with specificity 0.89 (95% CI 164 
0.79 to 0.94). For both tests, the accuracy parameters were heterogeneous with greater 165 
variability in sensitivity than specificity (Figure 3), 95% prediction contour was visibly wider 166 
for the combined markers (Appendix 5). The likelihood ratio of the positive test result for the 167 
urine dipstick test using only nitrites marker was 54.1 (95% CI 26.5 to 266.21. 168 
 169 
One study each contributed data on the specificity and sensitivity of chlorhexidine reaction and 170 
uriscreen catalase tests. The sensitivity of the former was 1.00 (95% 0.65 to 1.00) and 171 
specificity (0.54, 95% CI 0.46 to 0.62) (Table 2). Use of Griess test to detect the presence of 172 
nitrites was reported in two studies (728 women). The sensitivity of the test was comparable to 173 
Uriscreen catalase test 0.65 (95% CI 0.50 to 0.78) with a specificity of 0.99 (95% CI 0.98 to 174 
1.00). The likelihood of the positive test result was 56·6 (95% CI 12.6 to 255.1). Only one 175 
study reported the accuracy of the microscopic technique with the bacterial count in a 176 
centrifuged urine sample with a clearly defined threshold of more than 20 bacteria per High 177 
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Power Field (HPF). The sensitivity and specificity were 0.78 (95% CI 0.45 to 0.94) and 0.92 178 
(95% CI 0.88 to 0.94), respectively. 179 
 180 
Accuracy data of three dipslide-based tests included evaluation of Uricult (two studies), 181 
Microstix-3 (one study) and a generic dipslide method with gram stain dyeing and threshold of 182 
one or more bacteria per Oil Immersed Field (OIF) (six studies). Uricult had a sensitivity of 183 
0.92 (95% CI 0.69 to 1.00) and specificity 0.85 (95% CI 0.24 to 1.00). The dipslide with gram 184 
staining on uncentrifuged urine had sensitivity and specificity of 0.86 (95% CI 0.80 to 0.91) 185 
and 0.97 (95% CI 0.93 to 0.99) respectively (Figure 3). The likelihood ratio of the positive test 186 
result was 30.2 (95% CI 11.9 to 76.6). 187 
 188 
Sensitivity analysis was possible for dipstick with nitrites only as a marker, dipstick with 189 
nitrites or leukocytes and dipslide with gram staining. In all three cases, we explored the 190 
impact of population description and use of the sterile containers for urine storage. Neither of 191 
the factors changed the summary accuracy of the dipslide with gram staining. Analysis limited 192 
to studies with a clearly described population (asymptomatic women or not taking antibiotics) 193 
showed a marginal reduction in sensitivity (by 4%) for urine dipstick with positive leukocyte or 194 
nitrites marker. The pooled sensitivity of urine dipstick (nitrites with or without leukocytes) 195 
limited to studies providing details of urine container’s sterility, presented a minimal increase 196 
in parameter precision. Findings from studies with low risk of bias and studies where the type 197 
of urine sample was not properly described had a minimal impact on the sensitivity the dipstick 198 
test with no change in the value of the pooled specificity. 199 
 200 
Discussion 201 
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Out of 27 types of index tests identified in the literature, nine were suitable for use in the 202 
asymptomatic population. Three of them (urine dipstick, Griess test and dipslide with gram 203 
staining) had values of likelihood ratios for positive test result indicative of their usefulness 204 
(values > 10) in detecting asymptomatic bacteriuria during antenatal care. All test were minor 205 
to moderate usefulness to rule out the infection (likelihood ratios for negative result between 206 
0.5–0.1). 207 
 208 
This systematic review is the first comprehensive and robust synthesis of accuracy data 209 
concerning on-site tests to detect asymptomatic bacteriuria during antenatal care. Prospectively 210 
registered protocol with pre-specified population, reference standard, and definition of the 211 
outcome informed study selection, data extraction and analysis. On all stages of the review 212 
process, we followed current guidelines and standards.11 The literature search in electronic 213 
databases restricted to test accuracy studies due to pragmatic reasons was supplemented by 214 
manual reference check. The publication bias due to limitations of available statistical 215 
methods16, 17 was not investigated in this review, however, we did undertake an extensive 216 
exploration of the heterogeneity between estimates of tests accuracy in individual studies. 217 
 218 
The main limitation of this review was poor reporting in individual studies and paucity of data. 219 
The quality assessment was hindered by insufficient reporting of characteristics or recruited 220 
women, their flow through the study and timing between the use of index test and reference 221 
standard. Empirical evidence showed that test accuracy estimates can be affected by flaws in 222 
study design and its conduct.14 The estimates of test accuracy for four included tests were 223 
based on data from single studies with small sample sizes.22-24 This makes the parameters less 224 
reliable (wide confidence intervals) and more prone to chance findings. In order to compare the 225 
accuracy of all identified tests, we used the univariate model to pool sensitivity and specificity 226 
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estimates when less than four studies were available. Even though this approach does not 227 
account for correlation between two parameters as in the bivariate model, the findings should 228 
be fairly similar.25 Despite these limitations our findings merit consideration as the most robust 229 
and current evidence synthesis. 230 
 231 
The prevalence of asymptomatic bacteriuria in included studies ranged from 2 – 23% which 232 
overlaps with previously reported range1. The likelihood ratios of the positive test result for the 233 
urine dipstick test (only nitrites), Griess test and generic dip slide with gram staining (bacterial 234 
count > 1/OIF) were indicative of tests usefulness in ruling in asymptomatic bacteriuria.21 The 235 
likelihood ratio of positive result with Dipslide Uricult due to wide confidence intervals cannot 236 
be considered reliable. However, its likelihood ratio for the negative result was the only one 237 
indicative its usefulness to rule out the infection (< 0.1). Likelihood ratios can be used to help 238 
adapt the results of the findings to individual situation basing on Bayes’ theorem.26 With 239 
pretest probability derived from identified studies we calculate the posttest probability of 240 
having the infection with a positive and negative test result (Table 2). Two out of nine 241 
evaluated tests (urine dipstick with positive nitrites and Griess test) increased the probability 242 
from 8·0% to above 80.0% in case of positive result, and both reduced it by half in case of a 243 
negative result. Need for training and access to basic laboratory facilities might make Griess 244 
test and Gram staining less attractive than urine dipstick in resource-limited settings. 245 
 246 
Undetected and subsequently not treated asymptomatic bacteriuria is linked to pyelonephritis 247 
and other complications.3 Antibiotic treatment seem to reduce the risk of pyelonephritis in 248 
pregnancy and undesired pregnancy outcomes (preterm birth and low birth weight). Women 249 
incorrectly classified as positive (false positive) may be exposed to an unnecessary course of 250 
antibiotics with not well documented adverse effects.27 In light of lack of robust evaluation of 251 
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harms and increasing antimicrobial resistance, it is crucial to correctly identify women who 252 
will truly benefit from the treatment.8 253 
 254 
All identified on-site tests when positive increased posttest probability of detecting 255 
asymptomatic bacteriuria during the antenatal period. Urine dipstick, Griess test and dipslide 256 
with gram staining are most useful point-of-care options for ruling in the infection. Future 257 
research should aim to support the clinical decision-making on the management of 258 
asymptomatic pregnant women when access to urine culture is limited. 259 
 260 
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Table 1 Characteristics of studies evaluating accuracy of on-site tests to detect asymptomatic 1 
bacteriuria in antenatal care settings 2 
Study ID 
Publication 
Year 
Country 
Number of 
women 
Prevalence of  
the infection  
(95% CI) 
Index test(s) 
Abbasi 19851 1985 USA 65 0.05 (0.02–0.13) Dipstick 
Anandkumar 20112 2011 India 300 0.13 (0.09–0.17) 
Dipslide with gram 
staining 
Archbald 19843 1984 USA 287 0.03 (0.02–0.06) 
Dipstick, Urinalysis 
(bacteria count), 
Dipslide 
(Microstix–3) 
Awonuga 20114 2011 Nigeria 205 0.11 (0.07–0.16) Dipstick 
Bachman 19935 1993 USA 1047 0.02 (0.02–0.03) 
Dipstick, Dipslide 
with gram staining 
Balamurugan 20126 2012 India 100 0.13 (0.08–0.21) Dipstick 
Campos-Outcalt 
19857 
1993 USA 299 0.05 (0.03–0.08) Dipstick 
Demilie 20148 2014 Ethiopia 330 0.08 (0.06–0.12) Dipstick 
Eigbefoh 20089 2008 Nigeria 400 0.22 (0.18–0.26) Dipstick 
Gayathree 201010 2010 India 900 0.07 (0.05–0.09) 
Dipstick, Dipslide 
with gram staining 
Graninger 199211 1992 Germany 1000 0.13 (0.11–0.15) Dipstick 
Greeff 200212 2002 
South 
Africa 
247 0.23 (0.19–0.29) Dipslide (Uricult) 
Jayalakshmi 200813 2008 India 630 0.07 (0.06–0.10) 
Dipstick, Dipslide 
with gram staining 
Table 1 Study characteristics
Ewelina Rogozinska 
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Kacmaz 200614 2006 Turkey 250 0.04 (0.02–0.07) Dipstick 
Khattak 200415 2004 Pakistan 290 0.06 (0.04–0.10) Griess test 
Kovavisarach 
200816 
2008 Thailand 360 0.10 (0.07–0.14) Dipstick 
Mathews 199817 1998 India 438 0.07 (0.05–0.10) Griess test 
Mignini 200918 2009 Argentina 2353 0.14 (0.13–0.16) 
Dipstick, Dipslide 
(Uricult) 
Mukherjee 201519 2015 India 250 0.08 (0.06–0.12) 
Dipstick, Dipslide 
with gram staining 
Okusanya 201420 2014 Nigeria 150 0.05 (0.02–0.09) 
Dipstick, 
Chlorhexidine 
reaction 
Pallarés 199021 1990 Spain 74 0.12 (0.07–0.22) 
Dipstick, Dipslide 
with gram staining 
Plauche 198122 1981 USA 561 0.13 (0.09–0.18) Dipstick 
Shelton 200123 2001 USA 200 0.10 (0.07–0.15) Dipstick 
Soisson 198524 1985 USA 1062 0.06 (0.05–0.07) Dipstick 
Teppa 200525 2005 
Venezuel
a 
150 0.19 (0.13–0.26) 
Uriscreen catalase 
test 
Tincello 199826 1998 UK 893 0.05 (0.04–0.07) Dipstick 
Titoria 201427 2014 India 800 0.05 (0.04–0.07) Dipstick 
References of the included studies are available in Appendix 3 
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Table 1 Likelihood ratios and post-test probabilities for tests–detect asymptomatic bacteriuria 
in antenatal care settings 
*Pretest probability of 8.0% was a median prevalence derived from included studies 
Index test  
Likelihood ratio for  
a positive result 
(95% CI) 
Probability* 
of infection 
after 
positive 
testing (%) 
Likelihood ratio 
for a negative 
result 
(95% CI) 
Probability* 
of infection 
after 
negative 
testing (%) 
Dipstick: Nitrites 
positive 
54.08 (26.50–266.21) 82.5 0.46 (0.35–0.61) 3.9 
Dipstick: Leucocytes 
or nitrites positive 
6.36 (3.31–12.21) 35.6 0.31 (0.19–0.49) 2.6 
Chlorhexidine reaction 2.03 (1.58–2.61) 15.0 0.12 (0.01–1.71) 1.0 
Uriscreen catalase test 5.69 (3.15–10.32) 33.1 0.44 (0.27–0.70) 3.7 
Griess test (nitrites) 56.62 (12.57– 255.06) 83.1 0.36 (0.25–0.53) 3.0 
Urinalysis  
(bacteria count 
>20/HPF) 
9.4 (5.56–15.89) 44.9 0.24 (0.07–0.82) 2.1 
Dipslide with gram 
staining (bacteria 
count ≥1/OIF) 
30.22 (11.91–76.64) 72.4 0.14 (0.09–0.21)  1.2 
Dipslide (Uricult) 20.04 (0.01–5.2e+04) 63.5 0.09 (0.00–2.16)  0.8 
Dipslide (Microstix-3) 9.07 (5.21–15.77) 44.1 0.36 (0.18–0.74) 3.0 
Table 2 Likelihood ratios
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Records identified through 
database searching  
From inception to June 2015 
(n = 1,827) 
Sc
re
en
in
g 
In
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u
d
ed
 
El
ig
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ty
 
Id
en
ti
fi
ca
ti
o
n
 Additional records identified 
through reference search  
and other sources  
(n = 25) 
Records after duplicates removed  
(n = 1,360) 
Records screened  
(n = 1,360) 
Records excluded  
(n = 1,271) 
Full-text articles assessed 
for eligibility  
(n = 89) 
Full-text articles excluded  
(n = 50) due to:  
Population (n = 14) 
Reference standard (n = 12) 
Publication type (n = 5) 
Study design (n = 14) 
Data reporting issue (n = 5) 
Studies included before 
test evaluation (n = 39) 
Number of tests (n = 27) 
Studies included in the 
systematic review (n = 27) 
Number of tests (n = 9) 
Figure 1 Flow di gram describing studies and tests selection stages 
Tests excluded  
(n = 18) due to: 
Irrelevance to asymptomatic 
population (n = 5) 
Irrelevance to clinical 
practice (n = 11)  
Data concern (n = 2) 
Number of studies excluded 
due to irrelevant test (n = 12) 
Figure 1 Study selection
17
26
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10
4
1
5
0% 20% 40% 60% 80% 100%
Population Selection
Index Test
Reference Standard
*For Okusanya 2014 studies risk of bias for Chlorhexidine test unclear
Applicability
12
22*
21
9
15
5
4
18
2
0% 20% 40% 60% 80% 100%
Population Selection
Index Test
Reference Standard
Flow and Timing
Risk of bias
Figure 2 Study quality assessment using QUADAS-2 tool. Number of studies classified as low (light grey), unclear (dark grey) or high (black) risk of bias/concern for 
applicability
Figure 2 Quality assessment 
Dipstick: Nitrites positive
Dipstick: Leucocytes or nitrites positive
Chlorhexidine reaction
Uriscreen catalase test
Griess test (nitrites)
Urinalysis (bacteria count >20/HPF)
Dipslides with gram staining (bacteria count ≥1/OIF)
Dipslide (Uricult)
Dipslide (Microstix-3)
Index test
0.92 (0.69–1.00)
0.67 (0.41–0.85)
Sensitivity (95% CI)
0.55 (0.42–0.67)
0.73 (0.59–0.83)
1.00 (0.65–1.00)
0.61 (0.42–0.76)
0.65 (0.50–0.78)
0.78 (0.45–0.94)
0.86 (0.80–0.91)
0 0.5 1
0.85 (0.24–1.00)
0.93 (0.89–0.95)
0.99 (0.98–0.99)
0.89 (0.79–0.94)
0.54 (0.46–0.62)
0.89 (0.83–0.94)
0.99 (0.98–1.00)
0.92 (0.88–0.94)
0.97 (0.93–0.99)
Specificity (95% CI)
0 0.5 1
N of participants (studies)
150 (1)
9,491 (21)
5,940 (8)
150 (1)
728 (2)
287 (1)
3,201 (6)
2,420 (2)
287 (1)
Figure 3 Overview of sensitivity and specificity of included tests to detect asymptomatic bacteriuria among pregnant women (for details see Appendix 4)
Figure 3 Overview of tests accuracy 
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Appendix 1 Search strategy in MEDLINE via Ovid (19th Aug 2014 repeated on 2nd June 
2015  
Item   Search term 
1. Pregnancy.mp. or exp Pregnancy/ 
2. exp Gravidity/ 
3. gravid*.mp. 
4. gestation*.mp. 
5. exp Pregnant Women/ 
6. pregnant wom#n.mp. 
7. (child adj3 bearing).mp. 
8. childbearing.mp. 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. exp sensitivity/ 
11. exp specificity/ 
12. 10 and 11 
13. (predictive adj3 value$).tw. 
14. (sensitivity or specificity).tw. 
15. exp Diagnostic Errors/ 
16. ((false adj positiv$) or (false adj negativ$)).tw. 
17. (observer adj variation$).tw. 
18. (roc adj curve).tw. 
19. (likelihood adj3 ratio$).tw. 
20. exp Likelihood Functions/ 
21. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. exp bacteriuria/ 
23. (asymptomatic$ adj2 bacteriuria$).tw. 
24. exp Urinary Tract Infections/ 
25. 22 or 23 or 24 
26. 9 and 21 and 25 
Print Appendix
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Appendix 2 Overview of test to detect asymptomatic bacteriuria reported in the retrieved literature       
Group No. Index test Decision Justification for exclusion 
Dipstick 1 Dipstick (marker: nitrites) Include  
 2 Dipstick (marker: leucocytes or nitrites) Include  
 3 Dipstick (marker: leucocytes) Exclude Population: Information not useful in asymptomatic population 
 4 Dipstick (marker: leucocytes and nitrites) Exclude Population: Information not useful in asymptomatic population 
Culture methods  
(Dip slides) 
5 Uricult & Uricult Trio (Orion Diagnostica)^ Include  
6 Testuria (Ayerst Labs) Exclude Relevance to clinical practice: irrelevance to current clinical practice 
 7 Bacturcult (Wampole Labs) Exclude Relevance to clinical practice: irrelevance to current clinical practice 
 8 Microstix-3  Include  
 9 Generic dipslide Exclude Relevance to clinical practice: lack of information about threshold 
Microscopic 
techniques 
10 
Microscopic analysis of urine  
(marker & threshold: >20 bacteria per High Power Field 
Include  
 11 
Dip slide with gram staining  
(marker & threshold: ≥1 bacteria per oil immersed field) 
Include  
 12 
Microscopic analysis of urine  
(marker: leucocytes) 
Exclude Population: Not suitable to use in asymptomatic population 
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Group No. Index test Decision Justification for exclusion 
Microscopic 
techniques 
13 
Dip slide with gram staining  
(threshold ≥2 bacteria per oil immersed field) 
Exclude  Relevance to clinical practice: Excluded due to a threshold  
Tests not usually 
used to detect 
bacteriuria 
14 Uriscreen catalase tests (Savyon Diagnostics) Include  
15 Chlorhexidine reaction Include  
 16 Uriglox (glucose level) Exclude 
Relevance to clinical practice: Test used to detect the presence or absence of the small 
physiological amount of glucose  
(2-20 mg per 100 ml) 
Tests not usually 
used to detect 
bacteriuria 
17 Griess test (test to detect nitrites) Include  
18 Lumac/3M Bacteriuria Screening Kit RLU>200 Exclude 
Relevance to clinical practice: The test procedure is based upon firefly luciferase 
analysis of bacterial ATP. Exclude from further work as it requires lab facility 
 19 Interleukin-8 5 ≥264 pg/mL Exclude 
Relevance to clinical practice: Interleukin-8 (IL-8), an inflammatory cytokine, is 
involved in host response to infection through neutrophil chemo attraction. Exclude from 
further work as it requires lab facility 
 20 Chromogenic limulus assay Exclude 
Relevance to clinical practice: Not taken further due to identification of only gram 
negative pathogens 
 21 Catalase tests  Exclude Data concern: Subgroup analysis limits spectrum 
 22 Triphenyl Tetrazolium Chloride Exclude Data concern: Subgroup analysis limits spectrum 
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Group No. Index test Decision Justification for exclusion 
Automatic analysis 23 
Automatic analysis of urine samples  
(marker & threshold: nitrites) 
Exclude Cost: Automated urine analysis is not widely available in resource limited settings 
 24 
Automatic analysis of urine samples  
(marker & threshold: >1200 bacteria per ml) 
Exclude Cost: Automated urine analysis is not widely available in resource limited settings 
 25 
Automatic analysis of urine samples  
(marker & threshold: leukocytes) 
Exclude Population: Information not useful in asymptomatic population 
 26 
Automatic analysis of urine samples  
(marker & threshold: leukocytes and nitrites) 
Exclude Population: Information not useful in asymptomatic population 
 27 
Automatic analysis of urine samples  
(Bac-T-Screen, Marion Labs) 
Exclude 
Relevance to clinical practice: Instrument is designed to provide a rapid, semi 
quantitative measurement of the bacteria present in urine specimens. Exclude from further 
work due to irrelevance to current clinical practice 
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Appendix 4 Details of urine sample collection, processing and storage in individual studies 
No. Study ID 
Descriptio
n of the 
population 
Urine 
collection 
Random 
voided or 
first 
morning 
sample 
Description 
of urine 
container 
Time before 
sending to lab 
Sample 
storage 
Sample 
centrifuging 
Max. time of 
sample storage 
T° 
Incubatio
n of urine 
culture 
Hours 
incubatio
n of urine 
culture 
1 Abbasi 1985 
women not on 
antibiotics 
clean catch 
midstream 
specimens 
unspecified unspecified unspecified unspecified centrifuged unspecified unspecified unspecified 
2 
Anandkumar 
2011 
asymptomatic 
women 
clean catch 
midsteram 
specimens 
unspecified sterile 1 hour unspecified uncentrifuged  unspecified 37°C 24 hours 
3 
Archbald 
1984 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
unspecified 
3 hours (for IT at 
place), samples 
sent to 
microbiology lab 
for UC 
unspecified centrifuged unspecified unspecified unspecified 
4 
Awonuga 
2011 
asymptomatic 
women 
clean catch 
midstream 
specimens 
unspecified sterile immediately 4°C unspecified unspecified unspecified unspecified 
5 
Bachman 
1993 
women not on 
antibiotics 
clean catch 
midsteram 
specimens 
random 
voided, at 
place of care 
unspecified 45 minutes unspecified 
Dipstick: 
unspecified;           
Slide with gram 
staining: 
uncentrifuged 
unspecified unspecified unspecified 
6 
Balamurugan 
2012 
asymptomatic 
women 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
sterile 1 hour refrigerated centrifuged 4 hours unspecified unspecified 
7 
Campos 
Outcalt 1985 
lack of 
detailed 
information 
midstream 
specimens 
random 
voided, at 
place of care 
sterile unspecified unspecified unspecified unspecified unspecified unspecified 
8 
Demilie 
2014 
asymptomatic 
women 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
sterile 2 hours 4°C unspecified unspecified 
37°C 
aerobically 
24 hours 
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No. Study ID 
Descriptio
n of the 
population 
Urine 
collection 
Random 
voided or 
first 
morning 
sample 
Description 
of urine 
container 
Time before 
sending to lab 
Sample 
storage 
Sample 
centrifuging 
Max. time of 
sample storage 
T° 
Incubatio
n of urine 
culture 
Hours 
incubatio
n of urine 
culture 
9 
Eigbefoh 
2008 
asymptomatic 
women 
clean catch 
midstream 
specimens; 
catheterizati
on (8 
women) 
random 
voided, at 
place of care 
sterile 1 hour unspecified uncentrifuged  unspecified 37°C 24 hours 
10 
Gayathree 
2010 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
unspecified sterile 1 hour refrigerated uncentrifuged  unspecified 
35°C 
aerobically 
18-24 hours 
11 
Graninger 
1992 
women not on 
antibiotics 
clean catch 
midstram 
specimems  
unspecified unspecified 30 minutes unspecified unspecified unspecified 35°C  18 hours 
12 Greeff 2002 
asymptomatic 
women 
midstrean 
specimens 
random 
voided, at 
place of care 
unspecified unspecified unspecified uncentrifuged  unspecified unspecified unspecified 
13 
Jayalakshmi 
2008 
lack of 
detailed 
information 
clean catch 
midstream 
specimes 
unspecified unspecified 1 hour unspecified uncentrifuged  unspecified 
37°C 
aerobically 
24 hours 
14 
Kacmaz 
2006 
asymptomatic 
women 
clean catch 
midstream 
specimens 
unspecified sterile 1 hour 4°C unspecified 4 hours unspecified 
12-24-48 
hours 
15 Khattak 2004 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
sterile immediately unspecified unspecified unspecified 37°C unspecified 
16 
Kovavisarac
h 2008 
asymptomatic 
women 
clean catch 
midstrem 
specimes 
random 
voided, at 
place of care 
sterile 30 minutes unspecified unspecified unspecified 35-37°C 24-48 hours 
17 
Mathews 
1998 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
unspecified immediately unspecified unspecified unspecified unspecified unspecified 
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No. Study ID 
Descriptio
n of the 
population 
Urine 
collection 
Random 
voided or 
first 
morning 
sample 
Description 
of urine 
container 
Time before 
sending to lab 
Sample 
storage 
Sample 
centrifuging 
Max. time of 
sample storage 
T° 
Incubatio
n of urine 
culture 
Hours 
incubatio
n of urine 
culture 
18 
Mignini 
2009 
asymptomatic 
women 
clean catch 
midstream 
specimens 
random 
voided, at 
place of care 
sterile 1 hour 4°C unspecified 4 hours 37°C 24 hours 
19 
Mukherjee 
2014 
asymptomatic 
women 
clean catch 
midstream 
specimens 
unspecified sterile 1 hour 4°C uncentrifuged  24 hours 
37°C 
aerobically 
24-48 hours 
20 
Okusanya 
2014 
asymptomatic 
women 
clean catch 
midstream 
specimens 
unspecified sterile 1 hour 4°C  
Dipstick: 
uncentrifuged; 
Chlorhexidine 
reaction: 
unspecified 
unspecified unspecified unspecified 
21 Pallarés 1990 
women not on 
antibiotics 
clean catch 
midstream 
specimens 
first morning sterile 90 minutes 4°C unspecified unspecified 35-35°C  24 hours 
22 Plauche 1981 
asymptomatic 
women 
clean catch 
midstream 
specimens 
unspecified sterile 30 minutes unspecified unspecified unspecified unspecified unspecified 
23 Shelton 2001 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
unspecified unspecified immediately unspecified unspecified unspecified 37°C 24 hours 
24 Soisson 1985 
lack of 
detailed 
information 
clean catch 
midstream 
specimens 
unspecified unspecified unspecified unspecified unspecified unspecified unspecified unspecified 
25 Teppa 2005 
asymptomatic 
women 
in-and-out 
sterile 
technique of 
catheterizati
on  
first morning 
or random 
voided 4 
hours of 
incubation 
sterile unspecified 4°C unspecified 4 hours unspecified unspecified 
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No. Study ID 
Descriptio
n of the 
population 
Urine 
collection 
Random 
voided or 
first 
morning 
sample 
Description 
of urine 
container 
Time before 
sending to lab 
Sample 
storage 
Sample 
centrifuging 
Max. time of 
sample storage 
T° 
Incubatio
n of urine 
culture 
Hours 
incubatio
n of urine 
culture 
26 
Tincello 
1998 
asymptomatic 
women 
midstream 
specimens 
random 
voided, at 
place of care 
unspecified unspecified unspecified unspecified unspecified unspecified unspecified 
27 Titoria 2014 
asymptomatic 
women 
clean catch 
midstream 
specimens 
random 
voided 
sterile 4 hours unspecified uncentrifuged  unspecified unspecified unspecified 
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Appendix 5 Overview of sensitivity and specificity reported in studies included in the review 
by test 
 
Figure 1 Overview of sensitivity and specificity in individual studies reporting use of dipstick test 
(only nitrites marker positive) in detecting asymptomatic bacteriuria among pregnant women  
 
Figure 2 Receiver operating characteristic plots for studies evaluating accuracy of dipstick test (only 
nitrites marker positive) in detecting asymptomatic bacteriuria among pregnant women 
12 
 
 
 
Figure 3 Overview of sensitivity and specificity in individual studies reporting use of dipstick test 
(nitrites or leucocytes marker positive) in detecting asymptomatic bacteriuria among pregnant women 
 
Figure 4 Receiver operating characteristic plots for studies evaluating accuracy of dipstick test 
(nitrites or leucocytes marker positive) in detecting asymptomatic bacteriuria among pregnant women 
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Figure 5 Overview of sensitivity and specificity in individual studies reporting use of dipslide with 
gram straining (more than one bacteria per OIF) in detecting asymptomatic bacteriuria among 
pregnant women
 
Figure 6 Overview of sensitivity and specificity in individual studies reporting use of remaining tests 
in detecting asymptomatic bacteriuria among pregnant women 
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repeated.  
Supplementary 
materials 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
5-6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
6 
 
Page 1 of 2  
PRISMA Checklist
PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
6 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
7 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  - 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Supplementary 
materials 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  8-9 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  7-8, Figure 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  9 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
10 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
10-11 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  11-12 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
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